PhRMA: protect authorized generics

Share this article:

The Pharmaceutical Research and Manufacturers of America is defending industry patent settlements after an August 31 FTC report on authorized generics. PhRMA lauded the report's finding that an authorized generic is tied to lower prices for generics on the market before a 180-day market-exclusivity period's end, but added that a “potentially valuable report”  furthered an attack on patent settlements. 

“Authorized generics have not discouraged the availability of generics to patients,” the group stated. “Nearly 80% of prescriptions in the United States are already for generics, and the number of branded products facing Paragraph IV patent challenges has continued to grow.”

But FTC chairman Jon Leibowitz says  “brand companies may be using the threat of launching an authorized ge-neric as a powerful inducement for generic companies to delay bringing their drugs to market.” 

The FTC noted that more innovative drug companies are starting to market authorized generics while a generic firm is beginning its 180-day marketing exclusivity period, leading to questions about the effects of authorized generics on drug competition.

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Features

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?